title: Comparative in vitro activities of ceftaroline and ceftriaxone against bacterial pathogens associated with respiratory tract infections: results from the AWARE surveillance study.
abstract: Ceftaroline fosamil is indicated for the treatment of community-acquired bacterial pneumonia and ceftriaxone has an indication for lower respiratory tract infections. This study was conducted to compare the relative in vitro activities of these two agents against bacterial species associated with community-associated respiratory tract infections.
  
  
  
  In all, 13 005 isolates of Staphylococcus aureus, Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae were collected in 2012-14 from 39 countries in the Asia-Pacific region, Europe, Latin America and Africa-Middle East from respiratory tract specimens. The identification was confirmed centrally by MALDI-TOF and broth microdilution susceptibility testing and interpretation was done according to CLSI guidelines.
  
  
  
  Ceftaroline was 16-fold more potent against MSSA (MIC900.25 versus 4 mg/L) than ceftriaxone and ≥16-fold more potent against MRSA (MIC902 versus >32 mg/L). Ceftaroline was 16-fold more potent against S. pneumoniae (MIC900.12-0.25 mg/L) compared with ceftriaxone (MIC901-2 mg/L), with higher MIC values observed among penicillin-non-susceptible isolates for both agents. Similar activity (MIC90≤0.03 mg/L) was observed for ceftaroline and ceftriaxone against H. influenzae, with higher MIC values observed in the Asia-Pacific region for both agents compared with other regions. Ceftaroline was 4- to 8-fold more active against M. catarrhalis (MIC900.12-0.25 mg/L) compared with ceftriaxone (MIC901 mg/L).
  
  
  
  These global MIC data demonstrated that ceftaroline exhibited superior in vitro activity compared with ceftriaxone against bacterial species that commonly cause community-associated respiratory tract infections.
authors: IHMA, Inc., Schaumburg, IL, USA dbiedenbach@ihmainc.com.
authors: D J
authors: DJ
authors: Biedenbach
authors: AstraZeneca Pharmaceuticals LP, Waltham, MA, USA.
authors: J P
authors: JP
authors: Iaconis
authors: IHMA, Inc., Schaumburg, IL, USA.
authors: D F
authors: DF
authors: Sahm
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001419:Bacteria / Q000145:classification / Q000187:drug effects* / Q000302:isolation & purification; D001424:Bacterial Infections / Q000382:microbiology*; D002443:Ceftriaxone / Q000494:pharmacology*; D002511:Cephalosporins / Q000494:pharmacology*; D017714:Community-Acquired Infections / Q000382:microbiology; D062665:Epidemiological Monitoring; D005260:Female; D014943:Global Health; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D012141:Respiratory Tract Infections / Q000382:microbiology*; D000097583:Ceftaroline
chemical_list: D000900:Anti-Bacterial Agents; D002443:Ceftriaxone; D002511:Cephalosporins; D000097583:Ceftaroline